Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 10:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Pancreatic Cancer
Interventions: Volociximab, Gemcitabine; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Nashville, Tennessee

Conditions: Pulmonary Fibrosis
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2035
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: H.P. Acthar gel; Drug
Lead sponsor: Iraj Sabahi Research Inc.; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Pleasanton, California • Turlock, California

Conditions: Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: vorinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: UTI, Stone, Kidney
Interventions: Storz Flex-XC1 Disposable Flexible Ureteroscope, Storz Flexible Digital Ureteroscope; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
Interventions: IV L-carnitine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Months to 12 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Covid19
Interventions: COVID-19 Monitoring Using Wearable Sensors and Smartphone Technology; Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Liver Diseases, Healthy, Cirrhosis, Liver, Fibrosis
Interventions: Group K Diagnostic point of care device; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Mental Illness
Interventions: Express Access; Behavioral
Lead sponsor: Outcome Referrals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Framingham, Massachusetts

Conditions: Obesity, Morbid Obesity
Interventions: Transcend II Model 8848; Device
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Gainsville, Florida • Chicago, Illinois + 5 more

Conditions: Chronic Kidney Disease, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non-Hodgkin's Lymphoma (NHL)
Interventions: Bendamustine hydrochloride, Ofatumumab; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 34
States / cities: Birmingham, Alabama • Beverly Hills, California • Stamford, Connecticut + 30 more

Conditions: Substance Use Disorders, Alcohol Use Disorder, Opioid Use Disorder
Interventions: Not listed
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 185,810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcopenia
Interventions: Aerobic exercise training, Strength training; Other
Lead sponsor: Baltimore VA Medical Center; Federal
Eligibility: 65 Years to 88 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • College Park, Maryland

Conditions: Opioid-Related Disorders
Interventions: Cycloserine; Drug
Lead sponsor: Yale University; Other
Eligibility: Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 1998
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Solid Pancreatic Mass Lesions, Malignant Neoplasm of Pancreas
Interventions: Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle; Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions: Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery; Procedure · Other · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Sugar Land, Texas

Conditions: Uncontrolled Hypertension
Interventions: RHYTHM (Remote Hypertension Tracking Help Management), Enhanced usual care (UC); Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years to 85 Years
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Upper Respiratory Tract Infection
Interventions: Hyland's Cold 'n Cough 4 Kids; Drug
Lead sponsor: University of Washington; Other
Eligibility: 24 Months to 59 Months
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Open-angle Glaucoma, Oular Hypertension
Interventions: Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL, Anecortave Acetate Vehicle; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Renal Insufficiency, Diabetes Mellitus
Interventions: Iodixanol 320-Arm 1, Iopamidol 300-Arm 2; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Prostate Cancer, Prostatic Cancer, Prostatic Neoplasms, Prostate Neoplasms, Cancer of the Prostate
Interventions: CyberKnife Stereotactic Radiosurgery - Low Risk, CyberKnife Stereotactic Radiosurgery - Intermediate Risk; Radiation
Lead sponsor: Accuray Incorporated; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 307 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 18
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 15 more

Conditions: Advanced Cancer
Interventions: ZL-1201; Drug
Lead sponsor: Zai Lab (Shanghai) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 5
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more

Search by objective public record fields.

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF)

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

Vorinostat in Treating Patients With Acute Myeloid Leukemia

Evaluation of Novel Disposable Flexible Ureteroscope for the Treatment of Renal Calculi

Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

Monitoring Health Care Workers at Risk for COVID-19 Using Wearable Sensors and Smartphone Technology

Validation of Point of Care Liver Function Tests

Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology

Behavioral Health Referrals Study

Study of Weight Loss Using Gastric Stimulation in Obese Patients

Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic

Muscle Capillarization and Sarcopenia

Neurobiology of Opioid Dependence: 3 - 3

Comparison of a Novel 22-gauge Core Biopsy Needle

Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study

Remote Hypertension Management for Black Patients

Homeopathic Cold Medicine for Children

Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension

Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography

CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry

A Trial of ZL-1201 in Subjects With Advanced Cancer